$MSTX BakerBros 4.7 mill. Sabby 3 million ,
Sickle cell disease (also referred to as SCD) is an inherited disease which causes red blood cells to be sickle shaped, instead of circular. It is characterized by vaso-occlusive crises. The sickle shaped cells do not flow easily and have a tendency to adhere to each other and the walls of blood vessels. When this occurs, organs are deprived of oxygen. This causes permanent internal damage and is very painful. SCD is a deadly disease. Accumulation of organ damage often results in victims dying in mid-adulthood. There is currently no effective treatment for a patient having a sickle cell crisis. The average duration of a crisis is 3-5 days, but can last longer than a week. Current treatment involves opioid and anti-inflammatory drugs. In severe cases, a blood transfusion is necessary.
Mast Therapeutics' lead product candidate is named MST-188 and is currently in Phase 3 FDA trials. The main application being targeted by Mast for this drug is treatment of SCD crises. Clustering of red blood cells in a crisis causes vessel membrane damage. Damaged membrane tissue is rough and adhesive, which results in further aggregation of red blood cells. MST-188 binds to cell membranes and provides a hydrated, non-adhesive surface, thereby increasing blood flow.
Always place Stop Loss order after buying a stock to minimize losses.I lost 100k by not doing so.We learn from our mistakes or may be from others who have done those.
Singh
